Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors.
暂无分享,去创建一个
[1] Irene L Andrulis,et al. The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors , 2007, BMC Cancer.
[2] F. Halberg,et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis , 2006, Cancer science.
[3] S. Gery,et al. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. , 2006, Molecular cell.
[4] Cheng Chi Lee. Tumor Suppression by the Mammalian Period Genes , 2006, Cancer Causes & Control.
[5] S. Hankinson,et al. Night Work and Risk of Breast Cancer , 2006, Epidemiology.
[6] Ming-Feng Hou,et al. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. , 2005, Carcinogenesis.
[7] L. Fu,et al. The circadian clock: pacemaker and tumour suppressor , 2003, Nature Reviews Cancer.
[8] I. Andrulis,et al. HER‐2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry , 2002, Cancer.
[9] Peng Huang,et al. The Circadian Gene Period2 Plays an Important Role in Tumor Suppression and DNA Damage Response In Vivo , 2002, Cell.
[10] M. J. van de Vijver,et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] R. Stevens,et al. Night shift work, light at night, and risk of breast cancer. , 2001, Journal of the National Cancer Institute.
[12] F Laden,et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. , 2001, Journal of the National Cancer Institute.
[13] J. Sambrook,et al. Molecular Cloning: A Laboratory Manual , 2001 .
[14] S. Bull,et al. Preferential allelic expression can lead to reduced expression of BRCA1 in sporadic breast cancers , 1998, International journal of cancer.
[15] S. Bull,et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] N. Boyd,et al. Characteristics associated with participation at various stages at the Ontario site of the cooperative family registry for breast cancer studies. , 2002, Annals of epidemiology.
[17] P. Ravdin. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer , 1999 .
[18] A. Agresti. An introduction to categorical data analysis , 1997 .